AUS
NZ
UK
CA
USA
IND
Highlights
- - ASX saw remarkable gains with standout performances from various sectors in 2024.
- - Companies like (MSB) and (ZIP) marked impressive growth during the year.
- - The biotech, financial services, and technology sectors were key drivers of growth.
As 2024 draws to a close, the Australian Stock Exchange (ASX) has witnessed an exceptional year, with several companies delivering stellar performances despite broader market challenges. These successes span industries including biotechnology, financial services, healthcare, and resources, highlighting resilience and strategic growth across the board.
One standout is Mesoblast (ASX:MSB), which soared more than eightfold to become the year’s top performer. The Melbourne-based biotech achieved a major milestone with long-anticipated FDA approval, setting the stage for its U.S. expansion. Shares traded at $3.19 late in the year, reflecting its impressive trajectory.
Zip Co (ASX:ZIP) marked an extraordinary comeback, climbing by over threefold in value. The financial services provider, known for its buy-now-pay-later offerings, rebounded significantly from last year’s lows to end December at $2.96 per share, driven by strong market confidence.
Another notable winner is Findi Limited (ASX:FND), which delivered a gain of more than threefold. Heavily owned by retail investors, the company capitalized on market momentum, with shares closing the year at $4.77.
IperionX Limited (ASX:IPX) saw significant success in the materials sector, with its heavy investment in titanium production contributing to a substantial increase. The company’s advancements, such as completing its HAMR furnace project, were reflected in a share price rise exceeding 300%.
The technology sector also had its highlights, with NUIX Limited (ASX:NXL) doubling its value by overcoming past challenges. By improving its focus on operational quality, NUIX experienced a surge in market activity.
Health-related companies like Telix Pharmaceuticals (ASX:TLX) and Pro Medicus Limited (ASX:PME) were key contributors to the index’s strength. Regulatory approvals and strategic contracts helped these firms achieve significant gains.
Lastly, in the resource space, Spartan Resources (ASX:SPR) benefited from high-grade gold discoveries, while Sigma Healthcare (ASX:SIG) secured a critical merger with Chemist Warehouse to drive future growth.
Overall, 2024 has proven to be a landmark year for several ASX-listed companies, showcasing resilience and adaptability in challenging conditions. The achievements of these market leaders underscore the diverse opportunities available across Australia’s financial landscape.
